mortality/aging
|
• in pIpC-treated mice with the same timing as in pIpC-treated Nf1tm1Par/Nf1tm1Par Tg(Mx1-cre)1Cgn mice
|
immune system
|
• pIpC-treated mice develop myeloproliferative disorder with anemia unlike wild-type mice that is similar to in pIpC-treated Nf1tm1Par/Nf1tm1Par Tg(Mx1-cre)1Cgn mice
|
hematopoietic system
|
• pIpC-treated mice develop myeloproliferative disorder with anemia unlike wild-type mice that is similar to in pIpC-treated Nf1tm1Par/Nf1tm1Par Tg(Mx1-cre)1Cgn mice
|


Analysis Tools